Overview
Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist that took the crown from semaglutide as the most effective approved weight-loss medication. The SURMOUNT-1 trial showed average weight loss of up to 22.5% at the highest dose — numbers that begin to rival bariatric surgery.
Like semaglutide, it is a real, FDA-approved prescription medication with extensive human trial data.
How It Works
Tirzepatide activates both the GLP-1 receptor (like semaglutide) and the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) was long considered a minor player, but the dual agonism appears synergistic: greater appetite suppression, greater insulin sensitivity, and possibly improved fat metabolism compared to GLP-1 alone.
Why dual beats single
Head-to-head data (SURPASS-2) showed tirzepatide producing greater weight loss and HbA1c reduction than semaglutide 1 mg. The GIP component may also reduce the nausea burden at equivalent efficacy, though individual response varies.
Key Benefits
Weight loss — up to 22.5% average body weight reduction at 15 mg in trials, the best approved result to date.
Diabetes control — superior HbA1c reductions versus semaglutide, insulin and other comparators.
Sleep apnea — approved for obstructive sleep apnea in obesity after the SURMOUNT-OSA trials.
Cardiometabolic markers — improvements in blood pressure, lipids and liver fat.
Side Effects & Considerations
The side effect profile mirrors semaglutide: gastrointestinal symptoms dominate (nausea, diarrhea, vomiting, constipation), mostly during titration. The same boxed warning for thyroid C-cell tumors applies, with the same MEN2/MTC contraindications.
Same structural issues
Lean mass loss of 25-40% of total weight lost makes protein intake and resistance training essential. Weight regain after discontinuation is the rule. And the grey-market research peptide version carries the same purity, dosing and legality problems — this is a medication with a real, regulated supply chain; use it.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Approved titration (Zepbound) | 2.5 mg weekly, escalating every 4+ weeks | Once weekly subcutaneous | Chronic therapy | Titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Prescription only — follow the prescribing physician. |
Warnings
Prescription medication. Same thyroid carcinoma contraindications as semaglutide. Resistance training and protein are mandatory to limit muscle loss.